Engflag

Albiglutide

Quick links to important sections

Albiglutide

Albiglutide_HU

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Albiglutide

Property Description
Active ingredient Albiglutide
Form Solution for Subcutaneous Injection
Pharmacological class Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
General purpose Improving blood sugar control (Type 2 Diabetes)
Origin Biologic (Recombinant Fusion Protein)

Albiglutide is a prescription medicine (INN) belonging to the class of treatments known as GLP-1 Receptor Agonists. It is used to help manage blood sugar levels in adults with Type 2 diabetes mellitus, a general purpose clinically recognized for this therapeutic class. The medication's core function is to enhance the body's own regulatory processes to manage glucose.

Biologic Origin and Composition

The active ingredient is Albiglutide, which is classified as a unique recombinant fusion protein. This makes it a biologic drug created using specialized genetic technology.

Its chemical structure is engineered to be long-acting: it consists of two modified copies of the human GLP-1 hormone fragment fused to a natural carrier protein called human albumin. This fusion significantly slows down the rate at which the body breaks down the medication, supporting a reduced frequency of administration. The final product is administered as a clear solution for subcutaneous injection.

The General Goal of Albiglutide Treatment

The medication works by mimicking the effects of the natural incretin hormone GLP-1. It enhances the pancreas's ability to release insulin, but this action is glucose-dependent, meaning insulin release is stimulated mainly when blood sugar levels are elevated. This mechanism is pharmacologically supported to help reduce the risk of low blood sugar (hypoglycemia) compared to drug classes that drive insulin release regardless of glucose levels.

By helping the body respond better to high sugar levels, Albiglutide contributes to more consistent blood sugar regulation over time. It is typically prescribed to patients who require a sustained, yet less frequent, injectable option as part of their comprehensive diabetes management plan.

What side effects are possible with Albiglutide?

Possible side effects and safety information

The safety profile of Albiglutide is primarily categorized by the frequency and physiological system affected, based on official regulatory documents. The majority of documented adverse reactions are associated with the gastrointestinal system and the administration site.

Frequency-Classified Adverse Reactions

Regulatory sources classify the most common effects as follows:

  • Very Common (ge 10%): Nausea, Diarrhea, Upper respiratory tract infection, and Injection site reaction. Hypoglycemia is also classified as very common when the medicine is used with an insulin secretagogue or insulin.
  • Common (1% to 10%): Vomiting, Constipation, Dyspepsia, Back pain, Arthralgia (joint pain), and infections such as Sinusitis and Influenza.
  • Uncommon: Acute Pancreatitis and certain cardiac issues like Atrial flutter.

These gastrointestinal events often occur more frequently within the first six months of treatment initiation.

Serious Adverse Reactions and Safety Restrictions

Official labeling documents certain serious risks and constraints:

  • Serious Adverse Reactions include Acute Pancreatitis and the potential for Serious Hypersensitivity Reactions (e.g., angioedema). A Boxed Warning is included regarding the class risk of Thyroid C-Cell Tumors, based on animal data.
  • Safety Restrictions specify that Albiglutide is contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Population-Specific Safety Notes

The medicine is not recommended for use during pregnancy as it may cause fetal harm, and safety and efficacy have not been established in pediatric patients. Patients with severe renal impairment may experience a higher frequency of severe gastrointestinal effects, increasing the risk of dehydration.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Albiglutide

Overdose Scope Details based on Official Regulatory Documentation
Documented overdose presentations: Overdose manifestations are an exacerbation of the drug's pharmacological effects, primarily including severe hypoglycemia (low blood sugar), especially when co-administered with insulin or a sulfonylurea. High exposure may also result in profound gastrointestinal distress, such as severe nausea and severe vomiting.
Physiological systems affected (as stated in label): The physiological systems affected include the Metabolic System (hypoglycemia) and the Gastrointestinal System. Severe fluid loss due to vomiting and diarrhea poses a risk to the Renal System, potentially leading to acute kidney injury.
Dose-related or exposure-related factors (if applicable): Due to the long elimination half-life of this medication (approximately five days), the management of overdose symptoms requires a prolonged period of observation and treatment.
Population-specific overdose notes (if applicable): Patients with severe renal impairment are a higher-risk population, as they experienced a greater frequency of severe gastrointestinal reactions, which can exacerbate the risk of acute renal failure.
Emergency-response statements (as written in official documents): Management for overdose is symptomatic and supportive. No specific antidote is known.
When immediate medical help is required (label-derived phrasing only): Immediate medical attention is required when symptoms suggest Acute Pancreatitis (persistent, severe abdominal pain) or a Serious Hypersensitivity Reaction. Discontinuation of the medication is mandated promptly if these conditions are suspected.

Overdose Classifications (High-Level)

Classification Details based on Official Regulatory Documentation
Severity classification (as defined in official documents): Overdose manifestations are categorized based on the severity of pharmacological effects (e.g., severe hypoglycemia) and the risk of life-threatening outcomes (e.g., Acute Pancreatitis, Acute Renal Failure).
Regulatory basis (EMA / FDA / etc.): Information is based on official regulatory documents for the prescribing information.
Overdose-context constraints (as defined in official documents): No specific antidote is known for overdose, constraining management solely to supportive care.

Resulting Overdose Structure

Official overdose statements:

  • Overdose management is symptomatic and supportive, requiring observation and treatment over a potentially prolonged period due to the drug's long half-life.
  • Severe hypoglycemia is a key documented presentation, especially in patients co-administered insulin or a sulfonylurea.
  • Immediate discontinuation of Albiglutide is mandated if Acute Pancreatitis or a Serious Hypersensitivity Reaction is suspected, and prompt medical attention is required.
  • The risk of acute renal failure due to dehydration from severe gastrointestinal reactions is a specific complication noted, particularly in patients with pre-existing renal impairment.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Albiglutide overdose profile based on the exacerbation of known dose-dependent effects, primarily severe gastrointestinal upset and hypoglycemia. The profile mandates that when symptoms of serious conditions like Acute Pancreatitis or Acute Renal Failure are suspected, immediate medical intervention and drug discontinuation are required. The lack of a specific antidote necessitates a management strategy confined to supportive measures and continuous, potentially prolonged, patient monitoring as stated in the official labeling.

Therapeutic Uses of Albiglutide

Quick Facts

  • Therapeutic Domain: Improvement of blood sugar control.
  • Condition: Type 2 Diabetes Mellitus in adults.
  • Use Context: Intended as a complement to diet and exercise.

Albiglutide is indicated for adult patients with Type 2 Diabetes Mellitus to help with the management of blood glucose levels. Its use is an adjunctive therapy alongside appropriate diet modification and physical activity.

The primary therapeutic benefit is to contribute to improved glycemic control. Clinical evidence from trials suggests that this medication may achieve reductions in the measure of long-term blood sugar, known as glycosylated hemoglobin (HbA1c). This medication may be used as a monotherapy or in combination with other therapeutic agents for diabetes, such as metformin, sulfonylureas, or insulin.

It is important to note that Albiglutide is not intended for the treatment of Type 1 diabetes or diabetic ketoacidosis. The decision to use this medication should be made by a qualified healthcare professional. For full regulatory and prescribing details, consult the professional product labeling.

Eligibility and Restrictions for Use

Who Can and Cannot Use Albiglutide?

This section details the population eligibility and non-eligibility rules for Albiglutide, based strictly on official governmental regulatory documents.

Category Official Regulatory Statement
Approved Population Adult patients (aged 18 and older) with Type 2 Diabetes Mellitus.
Contraindicated Populations Patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Patients with a prior serious hypersensitivity reaction to Albiglutide or its components.
Conditions Not Indicated Type 1 Diabetes Mellitus or Diabetic Ketoacidosis.
Age-Related Rules Pediatric patients (under 18): Safety and efficacy have not been established; use is not recommended.
Organ Function Restrictions Hepatic Impairment: Use is not established due to a lack of clinical studies.
Severe Gastrointestinal Disease: Use is not recommended, as it has not been studied in patients with conditions like severe gastroparesis.
Pregnancy/Lactation Status Pregnancy: Should not be used. Discontinuation is advised at least one month before a planned pregnancy.
Lactation: A decision must be made to discontinue nursing or discontinue the medicine.

Official Eligibility Statements: Regulatory documents define absolute prohibitions for patients with MTC/MEN 2 and serious hypersensitivity. The medicine is explicitly not indicated for Type 1 Diabetes. Use is officially not recommended for pediatric patients and those with severe hepatic or severe gastrointestinal disease due to insufficient data to establish safety and efficacy.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Albiglutide

The interaction profile for Albiglutide is primarily defined by its effects on blood glucose management and gastrointestinal function, as documented by regulatory authorities.

Property Official Regulatory Statement
Medicinal product categories with documented interactions Insulin secretagogues (e.g., Sulfonylureas) and Insulin. Also, oral medications as a general class.
Mechanistic basis of interactions Delayed gastric emptying is the pharmacokinetic interaction basis.
Interaction-related restrictions Use is strictly contraindicated in patients with a prior serious hypersensitivity reaction to Albiglutide or its components. Alcohol may increase the risk of severe low blood sugar.
Timing-based interaction rules None documented as mandatory separation time requirements.

Resulting Interaction Structure

  • Co-administration with Insulin secretagogues or Insulin results in an officially classified increased risk of hypoglycemia.
  • The delay in gastric emptying may formally alter the absorption characteristics of any orally administered medications.
  • The use of Alcohol may potentiate the effects of antidiabetic agents, increasing the risk of low blood sugar.

The official profile is structured around a pharmacodynamic additive effect that mandates caution with other blood sugar-lowering therapies and a pharmacokinetic effect that defines the potential for altered absorption of oral co-administered medicines. These documented effects establish the interaction boundaries as defined by regulatory bodies.

Mechanism of Action

Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Its biological targets include the GLP-1 receptor found on the plasma membranes of pancreatic beta-cells, pancreatic alpha-cells, gastric mucosal cells, and neurons in the central nervous system.

In beta-cells, the drug-receptor interaction activates the cAMP/PKA signaling cascade and other intracellular pathways. This activation results in an increase in glucose-dependent insulin secretion from the beta-cells. Concurrently, the activation of GLP-1 receptors on alpha-cells leads to a suppression of glucagon secretion in a glucose-dependent manner.

At the systemic level, albiglutide modulates gastrointestinal physiology by delaying gastric emptying via neural pathways involving the vagus nerve and central nervous system nuclei. This physiological consequence results in a slower influx of nutrients, including glucose, into the circulation. The combined beta-cell stimulation, alpha-cell inhibition, and delayed gastric emptying result in a system-level modulation of plasma glucose concentrations and an overall reduction in endogenous glucose production.

Dosage and Administration Information

Administration Method

Albiglutide is administered as an injection under the skin (subcutaneous injection). Common injection sites include the abdomen, thigh, or upper arm. It is important to rotate the injection site with each dose to reduce the risk of skin irritation or tissue changes at the site of administration.

Preparation and Handling

The medication typically comes in a pen device that requires a reconstitution process before use. This process involves mixing a powder with a pre-filled liquid diluent. Once the medication is mixed, the solution should be inspected for clarity and color. The liquid should be clear and free of particles. If the solution is cloudy or contains visible debris, it should not be used.

Timing and Frequency

This medication is designed for long-acting use and is typically administered on the same day each week. It can be taken at any time of day, regardless of the timing of meals. If a change in the weekly administration day is necessary, it is generally managed by ensuring a minimum amount of time has passed since the last dose.

Storage Requirements

Proper storage is necessary to maintain the integrity of the medication. Before the first use, the pens are generally kept refrigerated. After the medication has been reconstituted or used for the first time, specific temperature ranges and time limits apply for room-temperature storage. The medication should be protected from direct heat and light at all times.

Recent Clinical Evidence

1. Evidence for Improved Blood Sugar Management

The core research for Albiglutide focused on studies evaluating its use in adults with Type 2 Diabetes. This was primarily conducted in a series of large, international research efforts, including Randomized Controlled Trials (RCTs). The studies monitored the long-term blood sugar marker by tracking a measurement called Glycosylated Hemoglobin (HbA1c), which provides an average reading over several months. Research examined Albiglutide in different scenarios, including patients using it as a single therapy alongside diet and exercise, and when added to existing diabetes medications like metformin or insulin. Studies monitored and reported changes in HbA1c levels in the studied groups compared to non-treatment groups (placebo) over approximately 52 weeks (one year). Research exploring its use alongside or compared to other medications within the same GLP-1 drug class found that findings varied across studies.

2. Research into Cardiovascular Outcomes

Beyond blood sugar markers, a large, dedicated study known as a Cardiovascular Outcomes Trial (CVOT) was conducted. This study design is used to research the effects of a medication on serious heart and blood vessel events. The CVOT research examined the occurrence of Major Adverse Cardiovascular Events (MACE), a composite endpoint that included cardiovascular death, non-fatal stroke, and non-fatal heart attack. This key study was conducted in a high-risk population: adults with Type 2 Diabetes who already had a history of established atherosclerotic cardiovascular disease. The findings describe patterns observed in the study, with event rates reported for the high-risk population compared to the placebo group over an intermediate period.

3. Long-Term Studies and What Is Uncertain

The research exploring Albiglutide was studied for varying lengths of time, with some trials monitoring effects for up to three years. Research provides context that these follow-up durations offer insight into how the medication is managed over short and intermediate timeframes. Nevertheless, information for the long-term outcomes and the durability of the observed findings over many years are not fully established by the existing published evidence. The most significant limitation is that the definitive cardiovascular findings were derived from a high-risk group; therefore, the scope of these findings for patients with Type 2 Diabetes who have not had prior cardiovascular events is less directly defined. Data for other groups, such as children or women who are pregnant, are not available from the primary regulatory research.

Key Studies & References Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy

How should Albiglutide be stored and disposed of?

Albiglutide (Tanzeum) is a biological product requiring adherence to strict temperature and handling rules, as defined in official regulatory labeling.

Storage Requirements

Storage State Required Condition Stability Limit
Unopened Pen Refrigerate at 36°F to 46°F (2°C to 8°C). Store until the expiration date.
Alternative Unopened Store at room temperature (up to 86°F/30°C). May be stored for a maximum of 4 weeks prior to use.
After Reconstitution At room temperature (up to 86°F/30°C). Must be used within 8 hours of mixing.

The pens must be kept in the original carton to protect the medicine from light. The product must not be frozen; discard immediately if freezing has occurred. For safety, the medicine must be stored out of the reach of children.

Disposal

Used pens and needles must be placed immediately into a dedicated, puncture-resistant sharps disposal container. The disposal of this container and any unused or expired medicine must follow specific state or local laws for sharps waste and should not be placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Albiglutide found in:

A-Z Index: